These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15834540)

  • 1. [Optimization of cholesterol reduction principles and clinical results of dual inhibition].
    von Hodenberg E
    Internist (Berl); 2005 May; 46 Suppl 1():S18-23. PubMed ID: 15834540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
    Vaverková H
    Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Guidelines of lipid therapy translation into clinical practice].
    Rosenberg M; Haass M
    Internist (Berl); 2005 May; 46 Suppl 1():S11-7. PubMed ID: 15864508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing LDL-C lowering with statins.
    McKenney JM
    Am J Ther; 2004; 11(1):54-9. PubMed ID: 14704596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
    Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDL reduction: how low should we go and is it safe?
    Robinson JG
    Curr Cardiol Rep; 2008 Nov; 10(6):481-7. PubMed ID: 18950559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ezetimibe with statins].
    Jublanc C; Giral P; Turpin G
    Presse Med; 2006 Mar; 35(3 Pt 2):487-94. PubMed ID: 16550148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
    Dagli N; Yavuzkir M; Karaca I
    Inflammation; 2007 Dec; 30(6):230-5. PubMed ID: 17687635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe.
    Garcia MM; Varela CG; Silva PF; Lima PR; Góes PM; Rodrigues MG; Silva Mde L; Ladeia AM; Guimarães AC; Correia LC
    Arq Bras Cardiol; 2016 Apr; 106(4):279-88. PubMed ID: 27142792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of plant sterols, lathosterol, oxidative stress and inflammatory markers after the combination therapy of ezetimibe and statin drugs in type 2 diabetic patients.
    Naruse R; Hori K; Terasawa T; Hara K; Suetsugu M; Takebayashi K; Morita K; Aso Y; Inukai T
    Obes Res Clin Pract; 2015; 9(1):67-74. PubMed ID: 25660177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
    Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
    Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe: a novel option for lowering cholesterol.
    Davidson MH
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antilipemic agents in combined therapy].
    Márk L; Császár A
    Orv Hetil; 2002 Aug; 143(34):1973-8. PubMed ID: 12422650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.